Pharmaids Pharmaceuticals Limited has announced the reconstitution of its Board Committees through a circular resolution passed on January 05, 2026. The pharmaceutical company informed the stock exchanges about these governance changes, which will take effect from January 06, 2026, in compliance with regulatory requirements.

Board Committee Restructuring

The company's Board of Directors approved the reconstitution of two key committees as part of its governance framework. This restructuring demonstrates the company's commitment to maintaining robust corporate governance standards and ensuring effective oversight mechanisms.

Audit Committee Composition

The reconstituted Audit Committee features a comprehensive structure with four members, maintaining a strong independent director presence:

The Audit Committee maintains its critical role in overseeing financial reporting, internal controls, and audit processes, with three independent directors ensuring objective oversight.

Nomination & Remuneration Committee Structure

The Nomination & Remuneration Committee has been reconstituted with three independent directors, ensuring complete independence in key personnel and compensation decisions:

This committee structure aligns with best practices in corporate governance, with Mr. Methuku Nagesh taking the leadership role as Chairman.

Regulatory Compliance

The reconstitution has been undertaken pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated these changes to BSE Limited, ensuring full transparency and regulatory compliance. The circular resolution mechanism demonstrates efficient decision-making processes within the company's governance framework.

Pharmaids Pharmaceuticals Limited has officially confirmed the appointment of Dr. Yogananda Moolemath as Independent Director effective January 01, 2026, following successful shareholder approval through postal ballot. The company has now filed the requisite regulatory disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Postal Ballot Results Overview

The company successfully concluded its postal ballot process on December 31, 2025, with shareholders approving key board appointments and remuneration proposals through remote e-voting. The postal ballot results were declared on January 02, 2026.

Independent Director Appointment Approved

Dr. Yogananda Moolemath's appointment as Independent Director was approved as a Special Resolution with overwhelming support from shareholders. The appointment follows the Board's earlier decision based on the recommendation of the Nomination and Remuneration Committee.

Director Profile and Qualifications

Dr. Yogananda Moolemath brings extensive expertise to the board as a European Registered Toxicologist (ERT) with a PhD in Toxicology and over 30 years of experience in Drug Discovery & Development, toxicology, regulatory science and research leadership.

Regulatory Compliance and Disclosure

The company has fulfilled all regulatory requirements under SEBI regulations, with Company Secretary Prasanna Subramanya Bhat confirming the appointment through official communication to BSE Limited. The disclosure confirms that Dr. Moolemath is not debarred from holding directorship by any regulatory authority.

Board Restructuring Progress

With Dr. Moolemath's appointment confirmed, the company's board restructuring initiatives continue to strengthen governance. The appointment complements other recent leadership changes, including the designation of Mr. P.N Vijay as Chairman and Dr. S.N Vinaya Babu as Vice Chairman in December 2025.

The successful completion of the postal ballot process and official appointment marks a significant milestone in Pharmaids Pharmaceuticals' governance enhancement, bringing specialized pharmaceutical industry expertise to the board through Dr. Moolemath's extensive background in drug development and regulatory affairs.